30 research outputs found
Deep Reinforcement Learning for Long Term Hydropower Production Scheduling
We explore the use of deep reinforcement learning to provide strategies for
long term scheduling of hydropower production. We consider a use-case where the
aim is to optimise the yearly revenue given week-by-week inflows to the
reservoir and electricity prices. The challenge is to decide between immediate
water release at the spot price of electricity and storing the water for later
power production at an unknown price, given constraints on the system. We
successfully train a soft actor-critic algorithm on a simplified scenario with
historical data from the Nordic power market. The presented model is not ready
to substitute traditional optimisation tools but demonstrates the complementary
potential of reinforcement learning in the data-rich field of hydropower
scheduling.Comment: 2020 International Conference on Smart Energy Systems and
Technologies (SEST
The Gait Deviation Index Is Associated with Hip Muscle Strength and Patient-Reported Outcome in Patients with Severe Hip Osteoarthritis:A Cross-Sectional Study
<p>A-B. Representative examples of the association between mGDI and clinical outcomes.</p
Is gait velocity and gait quality associated with hip muscle strength in hip osteoarthritis patients scheduled for total hip arthroplasty?
The effect of posterior and lateral approach on patient-reported outcome measures and physical function in patients with osteoarthritis, undergoing total hip replacement: a randomised controlled trial protocol
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
Background: Oral semaglutide is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for glycaemic control in patients with type 2 diabetes. Type 2 diabetes is commonly associated with renal impairment, restricting treatment options. We aimed to investigate the efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment. Methods: This randomised, double-blind, phase 3a trial was undertaken at 88 sites in eight countries. Patients aged 18 years and older, with type 2 diabetes, an estimated glomerular filtration rate of 30–59 mL/min per 1·73 m2, and who had been receiving a stable dose of metformin or sulfonylurea, or both, or basal insulin with or without metformin for the past 90 days were eligible. Participants were randomly assigned (1:1) by use of an interactive web-response system, with stratification by glucose-lowering medication and renal function, to receive oral semaglutide (dose escalated to 14 mg once daily) or matching placebo for 26 weeks, in addition to background medication. Participants and site staff were masked to assignment. Two efficacy-related estimands were defined: treatment policy (regardless of treatment discontinuation or rescue medication) and trial product (on treatment without rescue medication) in all participants randomly assigned. Endpoints were change from baseline to week 26 in HbA1c (primary endpoint) and bodyweight (confirmatory secondary endpoint), assessed in all participants with sufficient data. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered on ClinicalTrials.gov, number NCT02827708, and the European Clinical Trials Registry, number EudraCT 2015-005326-19, and is now complete. Findings: Between Sept 20, 2016, and Sept 29, 2017, of 721 patients screened, 324 were eligible and randomly assigned to oral semaglutide (n=163) or placebo (n=161). Mean age at baseline was 70 years (SD 8), and 168 (52%) of participants were female. 133 (82%) participants in the oral semaglutide group and 141 (88%) in the placebo group completed 26 weeks on treatment. At 26 weeks, oral semaglutide was superior to placebo in decreasing HbA1c (estimated mean change of −1·0 percentage point (SE 0·1; −11 mmol/mol [SE 0·8]) vs −0·2 percentage points (SE 0·1; −2 mmol/mol [SE 0·8]); estimated treatment difference [ETD]: −0·8 percentage points, 95% CI −1·0 to −0·6;
Deep Reinforcement Learning for Long Term Hydropower Production Scheduling
We explore the use of deep reinforcement learning to provide strategies for long term scheduling of hydropower production. We consider a use-case where the aim is to optimise the yearly revenue given week-by-week inflows to the reservoir and electricity prices. The challenge is to decide between immediate water release at the spot price of electricity and storing the water for later power production at an unknown price, given constraints on the system. We successfully train a soft actor-critic algorithm on a simplified scenario with historical data from the Nordic power market. The presented model is not ready to substitute traditional optimisation tools but demonstrates the complementary potential of reinforcement learning in the data-rich field of hydropower scheduling.acceptedVersio
Deep Reinforcement Learning for Long Term Hydropower Production Scheduling
We explore the use of deep reinforcement learning to provide strategies for long term scheduling of hydropower production. We consider a use-case where the aim is to optimise the yearly revenue given week-by-week inflows to the reservoir and electricity prices. The challenge is to decide between immediate water release at the spot price of electricity and storing the water for later power production at an unknown price, given constraints on the system. We successfully train a soft actor-critic algorithm on a simplified scenario with historical data from the Nordic power market. The presented model is not ready to substitute traditional optimisation tools but demonstrates the complementary potential of reinforcement learning in the data-rich field of hydropower scheduling